A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
The “2022 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs.
EyePoint Pharmaceuticals and OcuMension Therapeutics announced June 21 that China regulators had approved Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of chronic no...
Apellis Pharmaceuticals announced June 22 that it and partner Affilogic, of France, plan to submit an investigational new drug (IND) application to the US FDA within the next 12 months for APL-2006...
Medicare could have saved $3.6 billion in 2020 by purchasing generic drugs at the prices offered by Cost Plus Drug Company, the online pharmacy of Mark Cuban, according to research published June 2...
Researchers at the University of Utah John A. Moran Eye Center have revived photoreceptors in organ donor eyes and restored communication between them, according to research published in May in the...
Researchers say they’ve developed a “self-plugging” microneedle to deliver drugs to the eye that will reduce some of the risks of intravitreal injection with hypodermic needles, according to work p...
Aldeyra Therapeutics, of Lexington, Massachusetts, reported June 8 that its Phase III TRANQUILITY-2 trial for dry eye candidate reproxalap met its primary endpoints. Reproxalap was statistically su...
The Foundation Fighting Blindness reported June 21 that it had promoted Jason Menzo to chief executive officer (CEO) and Russell Kelley, PhD, MBA, to managing director of the Retinal Degeneration F...
Opus Genetics announced June 21 thatBen Yerxa, PhD, would become permanent chief executive officer after serving as acting CEO. Yerxa will leave his other positions as CEO of Foundation Fighting Bl...
On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.
Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.
Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.
Learn More Register TodayA Multi-Step Approach for Accurate & Timely Data
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.